Castle Biosciences

AdvanceAD-Tx evaluates the expression of 487 genes across 12 inflammatory and cutaneous biology pathways and reports one of two actionable molecular profiles—a JAK Inhibitor Responder Profile or a Th2 Molecular Profile—to help clinicians better understand the underlying immune biology of an individual patient’s disease. Full article: hubs.la/Q047CBcW0

💡 The 487-gene AdvanceAD-Tx GEP test helps predict which atopic dermatitis patients will respond to biologics vs need JAK inhibitors—potentially speeding effective treatment and reducing trial-and-error care. hubs.li/Q047kYRM0 #AtopicDerm #AD #GEP #DermTwitter

NOW PUBLISHED in Future Oncology: study results confirm that DecisionDx-Melanoma’s i31-SLNB identifies patients below the 5% National Comprehensive Cancer Network® (NCCN) threshold for forgoing sentinel lymph node biopsy (SLNB) and outperforms traditional staging criteria and other predictive gene expression profile (GEP) tests. 👉Among all patients studied, 2.6% nodal positivity and 97.8% three-year recurrence-free survival (RFS) was observed in those predicted to have less than 5% risk of a positive sentinel lymph node (SLN) by DecisionDx-Melanoma’s i31-SLNB 👉Only 1.4% SLN positivity was observed in patients with T1b–T2a tumors predicted to have less than 5% risk 👉Castle will host a webcast on Monday, March 23, at 4:30pm ET to discuss data from the publication. Highlights/webcast details: hubs.la/Q046LXw60

🏃‍♂️🏃‍♀️#TeamCastle recently laced up and hit the pavement for the firm-wide #CastleCares Charity Walk, now in its 5th year! Employees raised $10,345 for five partner organizations — The Skin Cancer Foundation, IMPACT Melanoma, Esophageal Cancer Action Network (ECAN), Melanoma Research Foundation, and A Cure In Sight (ACIS) — in support of the patient communities served by Castle's innovative portfolio of tests. This year's walk brings the total raised by Castle Cares Charity Walks to just over $43,000 — all contributed by Castle employees. A huge THANK YOU to everyone who participated! #CastleCulture #SpringIntoAction #WeLoveOurPeople❤️ @IMPACTMelanoma @ACureInSight1 @ECActionNetwork @CureMelanoma @SkinCancerOrg

“We now finally have a test that tells us, with a great degree of accuracy, whether the patient is likely to respond just to a biologic or is likely to need something more,” said Mark Lebwohl, MD, in a recent interview with @DermTimesNow discussing the benefits of the AdvanceAD-Tx 487-gene expression profile (GEP) test for moderate to severe atopic dermatitis (AD). Read more: hubs.la/Q046yxhB0

Recent @pulse2news in-depth interview with $CSTL Founder and CEO, Derek Maetzold. In the article, Derek discusses our mission to transform precision medicine through innovative molecular diagnostics and how our work is helping clinicians make more informed decisions and improve patient outcomes. Read the full interview here: hubs.la/Q046pBH70

Recently presented at the SSO Annual Meeting: NEW DATA from the largest prospective multicenter study to date evaluating DecisionDx-Melanoma’s integrated sentinel lymph node biopsy (i31-SLNB) test result confirms that the i31-SLNB accurately predicts sentinel lymph node (SLN) positivity and identifies low-risk patients who may safely consider forgoing SLNB while maintaining favorable long-term outcomes. Current National Comprehensive Cancer Network®(NCCN) Cutaneous Melanoma Guidelines recommend avoiding a sentinel lymph node biopsy (SLNB) if the predicted SLN positivity rate is less than 5%. This report shows that patients with a less than 5% predicted risk of SLN positivity by the DecisionDx-Melanoma test had an actual SLN positivity rate of just 2.6%, and only 1.4% in patients with T1b–T2a tumors specifically, again confirming the clinically actionable performance of DecisionDx-Melanoma. Highlights/details: hubs.la/Q046nh-y0

Closing out #pmwc26 with an engaging session led by @msirota84 & panel AI in Molecular Diagnostics: Integrating Multi-Omics & Clinical Data @ogevaert, @CastleBio, Lihua Jiang, Yunguan Wang pmwcintl.com/session/mar-6-…

🧬 Attending @PMWCintl - Precision Medicine World Conference this week? Don't miss this distinguished panel of experts, including Castle's Vice President of R&D, Rebecca Critchley-Thorne, who will discuss "AI in Molecular Diagnostics: Integrating Multi-Omics & Clinical Data" Friday at 3:45pm PT. Joining Rebecca are Marina Sirota (chair), Olivier Gevaert, Yunguan Wang, and Lihua Jiang. Schedule: hubs.la/Q045GcyJ0

Endoscopy On Air Americas brings you a message from @TissueCypher - Barrett's Esophagus:   Listen as Dr. Raman Muthusamy discusses the Barrett's Conundrum: Clinicians today have effective tools to treat #BarrettsEsophagus, but face a critical challenge of identifying which patients truly need intervention. #TissueCypher is "part of this umbrella of precision medicine," helping clinicians detect high-risk patients earlier and reduce progression to high-grade dysplasia or #EsophagealCancer.   Don't miss the 2026 Endoscopy School on Mar. 6! Register here 👇 endoscopyonair.com/event/acg-endo…

For tomorrow's #RareDiseaseDay, we'd like to recognize one that's close to our heart❤️: uveal (ocular) melanoma. While #UvealMelanoma👀 is indeed rare, affecting 5 - 6 out of 1 million people each year, it is actually the most common primary intraocular tumor in adults and is also the 2nd most common type of primary malignant melanoma—representing ~5%-6% of all melanoma diagnoses (second only to cutaneous melanoma). #DecisionDxUM is the standard of care for evaluating metastatic risk in uveal melanoma. hubs.la/Q0428DG30

JUST RELEASED: Castle Biosciences announces financial results for the 4th quarter and year ended 12/31/25. Highlights: Full-year 2025 revenue of $344 million (exceeded guidance); 2025 total test reports for core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 37% over 2024; year-end 2025 cash, cash equivalents and marketable investment securities of $300 million (as of 12/31/25). View further results and access the webcast here: ir.castlebiosciences.com/news/news-deta…

JOIN US TODAY: Castle will release Q4 and full-year 2025 financial results via a conference call and webcast at 4:30 pm ET. Registration/log-in details here: hubs.la/Q0428xMr0

.@CastleBio’s AdvanceAD-Tx test can identify patients with moderate-to-severe #atopicdermatitis who are significantly more likely to achieve greater & faster clinical responses when treated with a JAKi compared to T helper type 2 (Th2)-targeted therapies. jdnppa.com/castles-advanc…

Reflux doesn’t always feel like heartburn. It can show up as throat symptoms, chronic cough, chest discomfort, or other signs patients often overlook. GERD is also a known risk factor for Barrett’s esophagus — making recognition and monitoring important. Foregut surgeon Dr. Dan Lister explains what patients need to know. 🎧 Watch the full episode: bit.ly/4b89pAe Thank you @CastleBio for sponsoring this educational series. #GERD #BarrettsEsophagus #DigestiveHealth

Cancer prevention starts with knowing who's truly at risk. #TissueCypher provides personalized risk stratification for patients with #BarrettsEsophagus, helping focus surveillance and intervention where it matters most. #CancerPreventionMonth.

.@CastleBio's AdvanceAD-Tx test can identify patients with moderate-to-severe #atopicdermatitis who are significantly more likely to achieve greater & faster clinical responses when treated with a JAKi compared to T helper type 2 (Th2)-targeted therapies. thedermdigest.com/personalized-m…

A recent study led by Dr. J. William Harbour of UT Southwestern Medical Center marks a shift in how doctors predict the spread of #UvealMelanoma (UM). Published in Nature Communications, the COOG2 study confirms that combining the DecisionDx-UM gene expression profile with PRAME testing provides a more accurate roadmap for patient care than traditional DNA mutation analysis alone. Full article in @cure_today: hubs.la/Q0445Ssf0

NOW PUBLISHED in the Journal of the American Academy of Dermatology @JAADjournals: Study data show that AdvanceAD-Tx can stratify patients by molecular profile identifying those more likely to achieve near-clear skin (EASI-90), faster time to response, and meaningful patient-reported benefits when treated with JAK inhibitor therapy compared to a Th2-targeted therapy. Highlights/details: hubs.la/Q0441Y3F0